Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit–Risk Profile from the OCARINA II Study and Patient Preferences (P8-1.003)
To further characterize the benefit–risk profile of ocrelizumab (OCR) subcutaneous (SC) based on updated efficacy/safety data, and new patient-reported outcomes (PROs) from OCARINA II (NCT05232825), at the clinical cut-off date (CCOD; up to September 2024).
Authors
- Diego Centonze (ORCID: https://orcid.org/0000-0002-8390-8545)
- Jay Azmi
- Ewa Krzystanek (ORCID: https://orcid.org/0000-0003-4441-3088)
- Susanne Clinch (ORCID: https://orcid.org/0000-0002-3458-0117)
- Lawrence Goldstick
- Krzysztof Selmaj (ORCID: https://orcid.org/0000-0003-1213-7218)
- Caroline Giacobino
- Scott D. Newsome (ORCID: https://orcid.org/0000-0002-5284-4681)
- Dusanka Zecevic (ORCID: https://orcid.org/0000-0001-6719-9710)
- Catarina Figueiredo (ORCID: https://orcid.org/0000-0002-5404-782X)
Institutions
- Roche (Switzerland) (CH)
- Johns Hopkins University (US)
- Medical University of Silesia (PL)
- Johns Hopkins Medicine (US)
- Istituto Neurologico Mediterraneo (IT)
- Roche (United Kingdom) (GB)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210377
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00